On November 7, 2024, MAPS received notice from the FDA that the Phase 2 study of Cannabis for Veterans with PTSD (MJP2) is cleared to proceed with smoking as a delivery method. This update confirms that …
There is no excerpt because this is a protected post.
On October 10, 2024, MAPS submitted a Complete Response to FDA’s Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). This response addressed the four key clinical hold issues identified …
On September 19, 2024, MAPS received the response from the Office of Neuroscience to the Formal Dispute Resolution Request (FDRR) submitted by MAPS on August 23, 2024. The FDRR was submitted in response …
FOR IMMEDIATE RELEASE: August 27, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) awarded Emory University researchers a $200,000 grant for a pilot study examining MDMA-assisted Massed …
On August 23, 2024, MAPS submitted a Formal Dispute Resolution Request to appeal the Clinical Hold placed on the Phase 2 study of cannabis for Veterans with PTSD (MJP2) by the FDA Division of Psychiatry …
FOR IMMEDIATE RELEASE: August 9, 2024 Aug 9, 2024 – San Jose, CA – The Multidisciplinary Association for Psychedelic Studies (MAPS) is evaluating the path forward for safe, legal access to MDMA-assisted …
The History of SB 1012 Following Measure 109‘s success in November 2020 in Oregon, California Senator Scott Wiener introduced SB519 in January 2021. California Governor Gavin Newsom eventually vetoed …
Richard Nixon announced the War on Drugs in 1971 and, in doing so, perpetuated an ongoing rhetoric and myth of Black criminality. Ronald Reagan escalated the impact of this policy by prioritizing punishment …
Evidence demonstrates, and the general public believes, cannabis should be legal for adult use. President Biden has repeatedly promised to decriminalize cannabis, but even before the President’s proclamation, …
Join MAPS leaders Kris Lotlikar, Ismail Ali, J.D., Allison Coker, Ph.D., and Betty Aldworth to delve into the approaches and strategies MAPS is engaging during this critical juncture. After 38 years of …
Dear Friends and Allies, On June 4, 2024, the U.S. Food and Drug Administration (FDA) convened a meeting of the Psychopharmacologic Drugs Advisory Committee to evaluate Lykos Therapeutics’ (Lykos) New …
